PMID- 24673112
OWN - NLM
STAT- MEDLINE
DCOM- 20141230
LR  - 20151119
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 44
IP  - 6
DP  - 2014 Jun
TI  - Impaired resolution of inflammation in human chronic heart failure.
PG  - 527-38
LID - 10.1111/eci.12265 [doi]
AB  - BACKGROUND: Lipoxins (LXs) are proresolving and anti-inflammatory eicosanoids 
      whose role in chronic heart failure (CHF) pathogenesis has never been 
      investigated. This study evaluated levels of LXs in CHF patients, its 
      relationship with disease severity and correlation with established CHF 
      biomarkers. The effect of low-dose aspirin [acetylsalicylic acid (ASA)] on the 
      levels of LXs was also studied. MATERIALS AND METHODS: Lipoxin A4 (LXA4 ), 
      15-epi-lipoxin A4 (15-epi-LXA4 ) and myeloperoxidase (MPO) concentration and 
      activity were evaluated by immunoenzymatic and spectrophotometric assays in 34 
      CHF patients [New York Heart Association (NYHA) functional class I to IV]. B-type 
      natriuretic peptide (BNP), troponin, myoglobin, C-reactive protein (CRP) and uric 
      acid (UA) were also analyzed. RESULTS: Patients were stratified into 
      mild-to-moderate CHF (NYHA, classes I and II) and severe CHF (NYHA classes III 
      and IV). Severe patients had lower plasma LXA4 (0.262 +/- 0.034 vs. 
      0.362 +/- 0.039 ng/mL, P < 0.05) and decreased urinary 15-epi-LXA4 levels 
      (2.28 +/- 0.44 vs. 4.88 +/- 1.03 mug/day, P < 0.05) besides exhibiting increased 
      plasma BNP (1464 +/- 442 vs. 555 +/- 162 pg/mL, P < 0.05) and MPO activity 
      (45.15 +/- 11.56 vs. 15.90 +/- 2.80 mumol/min/mg protein, P < 0.05). Plasma LXA4 was 
      inversely correlated with BNP, troponin, myoglobin, CRP, UA and MPO activity. ASA 
      treatment was associated with higher urinary excretion of 15-epi-LXA4 
      (7.70 +/- 1.48 vs. 2.06 +/- 0.30 mug/day, P < 0.05) in mild-to-moderate CHF patients 
      and lower BNP levels in both groups. CONCLUSIONS: Higher severity of CHF is 
      associated with reduced levels of LXs. Plasma LXA4 appears to be a valuable 
      marker for risk stratification in CHF. Furthermore, the ASA-related increase in 
      urinary 15-epi-LXA4 suggests enhanced renal synthesis of this eicosanoid and may 
      represent a disregarded benefit of ASA.
CI  - (c) 2014 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Reina-Couto, Marta
AU  - Reina-Couto M
AD  - Departamento de Farmacologia e Terapeutica, Faculdade de Medicina da Universidade 
      do Porto, Porto, Portugal; MedInUP - Centro de Investigacao Farmacologica e 
      Inovacao Medicamentosa, Universidade do Porto, Porto, Portugal; Departamento de 
      Medicina Interna, Centro Hospitalar Sao Joao, Porto, Portugal.
FAU - Carvalho, Jorge
AU  - Carvalho J
FAU - Valente, Maria Joao
AU  - Valente MJ
FAU - Vale, Luis
AU  - Vale L
FAU - Afonso, Joana
AU  - Afonso J
FAU - Carvalho, Felix
AU  - Carvalho F
FAU - Bettencourt, Paulo
AU  - Bettencourt P
FAU - Sousa, Teresa
AU  - Sousa T
FAU - Albino-Teixeira, Antonio
AU  - Albino-Teixeira A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140422
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Lipoxins)
RN  - 0 (lipoxin A4)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology
MH  - Aspirin/administration & dosage/pharmacology
MH  - Biomarkers/metabolism
MH  - Cardiovascular Diseases/etiology
MH  - Chronic Disease
MH  - Female
MH  - Glomerular Filtration Rate/physiology
MH  - Heart Failure/*etiology
MH  - Humans
MH  - Inflammation/physiopathology
MH  - Leukocyte Count
MH  - Lipoxins/*metabolism
MH  - Male
MH  - Peroxidase/metabolism
MH  - Risk Factors
OTO - NOTNLM
OT  - Aspirin
OT  - biomarkers
OT  - chronic heart failure
OT  - lipoxins
OT  - resolution of inflammation
EDAT- 2014/03/29 06:00
MHDA- 2014/12/31 06:00
CRDT- 2014/03/29 06:00
PHST- 2014/01/10 00:00 [received]
PHST- 2014/03/25 00:00 [accepted]
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/12/31 06:00 [medline]
AID - 10.1111/eci.12265 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2014 Jun;44(6):527-38. doi: 10.1111/eci.12265. Epub 2014 Apr 
      22.